WO2011126071A1 - Agent capable d'inhiber une infection virale et/ou de traiter une maladie infectieuse et méthode d'inhibition d'une infection virale et/ou de traitement d'une maladie infectieuse - Google Patents

Agent capable d'inhiber une infection virale et/ou de traiter une maladie infectieuse et méthode d'inhibition d'une infection virale et/ou de traitement d'une maladie infectieuse Download PDF

Info

Publication number
WO2011126071A1
WO2011126071A1 PCT/JP2011/058804 JP2011058804W WO2011126071A1 WO 2011126071 A1 WO2011126071 A1 WO 2011126071A1 JP 2011058804 W JP2011058804 W JP 2011058804W WO 2011126071 A1 WO2011126071 A1 WO 2011126071A1
Authority
WO
WIPO (PCT)
Prior art keywords
virus
group
infection
viral infection
calcium
Prior art date
Application number
PCT/JP2011/058804
Other languages
English (en)
Japanese (ja)
Inventor
雄介 大場
忠昭 宮崎
Original Assignee
国立大学法人北海道大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人北海道大学 filed Critical 国立大学法人北海道大学
Publication of WO2011126071A1 publication Critical patent/WO2011126071A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • “suppressing infection” is used interchangeably with “preventing infection”, “preventing infection”, and “inhibiting infection”.
  • endocytosis is a general term for a method in which cells generally take in substances from the outside world into cells by vesicle formation and fusion. Endocytosis depends on the type and size of the substance to be taken in and the cellular equipment involved, depending on clathrin-independent endocytosis, clathrin-dependent endocytosis, macropinocytosis, caveolae-dependent endocytosis, It is classified into cholesterol-dependent endocytosis and dynamin-2-dependent endocytosis.
  • virus infection suppression and / or infectious disease therapeutic agent according to the present invention and the method for suppressing virus infection and / or treating infection will be described based on examples. Note that the technical scope of the present invention is not limited to the features shown by these examples.
  • PR8 virus was inoculated in the control group, the BB group, the NB group, and the BN group by the method described in Example 1 (3).
  • PR8 virus-containing medium supplemented with BAPTA-AM (Sigma) at 25 ⁇ mol / L was used.
  • PCR reaction solution composition dNTP 200 ⁇ mol / L, forward primer 300 nmol / L, reverse primer 300 nmol / L, template DNA 100 ng, MgCl 2 1.5 mmol / L, 1 ⁇ Expand High Fidelity Reaction buffer, Expand High Fidelity Enzyme mL / 52 mL PCR reaction conditions: after 2 minutes of reaction at 94 ° C., 30 cycles of 94 ° C. for 30 seconds, 55 ° C. for 30 seconds, 72 ° C. for 30 seconds, followed by 5 minutes at 72 ° C. Went.
  • Example (4) Detection with anti-hemagglutinin antibody and anti-calcium channel antibody
  • the liquids a, b, c, d and e of Example (4) were removed, and the washing buffer of Example (1) was added. Washed by shaking for 30 minutes at ° C. This washing operation was performed 3 times in total.
  • the average mRNA relative expression level of PR8 virus nucleoprotein is 1 time in the control group, about 0.75 times in the amlodipine group, about 0.4 times in the verapamil group, and in the diltiazem group. It was about 0.45 times. Further, in comparison with the control group, the verapamil group and the diltiazem group were significantly different.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un agent capable d'inhiber une infection virale et/ou de traiter une maladie infectieuse grâce auquel l'infection virale peut être inhibée, sans que ladite inhibition ne soit affectée par une modification du virus, telle que l'apparence d'une sous-espèce ou un variant, ainsi qu'une méthode d'inhibition d'une infection virale et/ou de traitement d'une maladie infectieuse. L'entrée d'un virus dans une cellule est inhibée grâce à l'utilisation, en tant que principe(s) actif(s), d'une substance capable d'inhiber l'entrée d'ions calcium dans les cellules et/ou d'une substance capable de former un chélate avec les ions calcium. En utilisant l'agent susmentionné en vue de l'inhibition d'une infection virale et du traitement d'une maladie infectieuse, il est possible d'inhiber une infection virale ou de traiter une maladie infectieuse provoquée par une grande diversité de souches virales sur une durée prolongée, sans que cela soit affecté par une modification du virus, telle que l'apparence d'une sous-espèce ou un variant.
PCT/JP2011/058804 2010-04-09 2011-04-07 Agent capable d'inhiber une infection virale et/ou de traiter une maladie infectieuse et méthode d'inhibition d'une infection virale et/ou de traitement d'une maladie infectieuse WO2011126071A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010090745A JP2013139391A (ja) 2010-04-09 2010-04-09 ウイルス感染抑制および／または感染症治療剤
JP2010-090745 2010-04-09

Publications (1)

Publication Number Publication Date
WO2011126071A1 true WO2011126071A1 (fr) 2011-10-13

Family

ID=44763006

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/058804 WO2011126071A1 (fr) 2010-04-09 2011-04-07 Agent capable d'inhiber une infection virale et/ou de traiter une maladie infectieuse et méthode d'inhibition d'une infection virale et/ou de traitement d'une maladie infectieuse

Country Status (2)

Country Link
JP (1) JP2013139391A (fr)
WO (1) WO2011126071A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016146836A2 (fr) 2015-03-19 2016-09-22 Universite Claude Bernard Lyon 1 Nouvelles compositions antivirales pour le traitement de la grippe
WO2019224489A1 (fr) 2018-05-23 2019-11-28 Universite Claude Bernard Lyon 1 Diltiazem pour son utilisation dans le traitement des infections microbiennes

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512325A (ja) * 1999-10-19 2003-04-02 ザ、プロクター、エンド、ギャンブル、カンパニー 感冒およびインフルエンザ様症状の予防並びに治療用組成物、並びにそれらの使用方法
US20060264510A1 (en) * 2000-05-19 2006-11-23 Bio-Defense Nutritionals Antiviral methods and compositions
JP2007533667A (ja) * 2004-04-22 2007-11-22 ハワード ジェイ． スミス アンド アソシエイツ ピーティーワイ エルティーディー 肝臓疾患の支持療法
JP2008538354A (ja) * 2005-04-08 2008-10-23 キメリクス，インコーポレイテッド ウイルス感染症およびその他の内科疾患を治療するための化合物、組成物および方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512325A (ja) * 1999-10-19 2003-04-02 ザ、プロクター、エンド、ギャンブル、カンパニー 感冒およびインフルエンザ様症状の予防並びに治療用組成物、並びにそれらの使用方法
US20060264510A1 (en) * 2000-05-19 2006-11-23 Bio-Defense Nutritionals Antiviral methods and compositions
JP2007533667A (ja) * 2004-04-22 2007-11-22 ハワード ジェイ． スミス アンド アソシエイツ ピーティーワイ エルティーディー 肝臓疾患の支持療法
JP2008538354A (ja) * 2005-04-08 2008-10-23 キメリクス，インコーポレイテッド ウイルス感染症およびその他の内科疾患を治療するための化合物、組成物および方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLOAD, P.A. ET AL.: "The inhibition of the RNA polymerase activity of influenza virus A by pyrophosphate analogues", NUCLEIC ACID RESEARCH, vol. 11, no. 16, 1983, pages 5621 - 5628 *
NUGENT, K.M. ET AL.: "Verapamil inhibits influenza A virus replication", ARCHIVES OF VIROLOGY, vol. 81, 1984, pages 163 - 170 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113876781A (zh) * 2015-03-19 2022-01-04 里昂第一大学 用于治疗流感的新型抗病毒组合物
FR3033701A1 (fr) * 2015-03-19 2016-09-23 Univ Claude Bernard Lyon Nouvelles compositions antivirales pour le traitement de la grippe
WO2016146836A3 (fr) * 2015-03-19 2016-11-03 Universite Claude Bernard Lyon 1 Nouvelles compositions antivirales pour le traitement de la grippe
CN107743402A (zh) * 2015-03-19 2018-02-27 里昂第大学 用于治疗流感的新型抗病毒组合物
JP2018508587A (ja) * 2015-03-19 2018-03-29 ウニベルシテ クロード ベルナール リヨン １ インフルエンザを治療するための新規抗ウイルス性組成物
WO2016146836A2 (fr) 2015-03-19 2016-09-22 Universite Claude Bernard Lyon 1 Nouvelles compositions antivirales pour le traitement de la grippe
US11351180B2 (en) 2015-03-19 2022-06-07 Universite Claude Bernard Lyon 1 Antiviral compositions for treating the flu
WO2019224489A1 (fr) 2018-05-23 2019-11-28 Universite Claude Bernard Lyon 1 Diltiazem pour son utilisation dans le traitement des infections microbiennes
FR3081325A1 (fr) * 2018-05-23 2019-11-29 Universite Claude Bernard Lyon 1 Diltiazem pour son utilisation dans le traitement des infections microbiennes
CN112789046A (zh) * 2018-05-23 2021-05-11 里昂第一大学 地尔硫卓用于治疗微生物感染
JP2021525250A (ja) * 2018-05-23 2021-09-24 ウニベルシテ クロード ベルナール リヨン １ 微生物感染の治療における使用のためのジルチアゼム
JP7412353B2 (ja) 2018-05-23 2024-01-12 ウニベルシテ クロード ベルナール リヨン １ 微生物感染の治療における使用のためのジルチアゼム
CN112789046B (zh) * 2018-05-23 2024-02-20 里昂第一大学 地尔硫卓用于治疗微生物感染

Also Published As

Publication number Publication date
JP2013139391A (ja) 2013-07-18

Similar Documents

Publication Publication Date Title
Vanderlinden et al. Novel inhibitors of influenza virus fusion: structure-activity relationship and interaction with the viral hemagglutinin
Kohio et al. Glycolytic control of vacuolar-type ATPase activity: a mechanism to regulate influenza viral infection
Cheng et al. Two years after pandemic influenza A/2009/H1N1: what have we learned?
US9573991B2 (en) Human monoclonal antibodies derived from human B cells and having neutralizing activity against influenza A viruses
AU2018218179A1 (en) Methods of treating influenza
US10801077B2 (en) Influenza A virus variants
Vanderlinden et al. Intracytoplasmic trapping of influenza virus by a lipophilic derivative of aglycoristocetin
AU2015325012A1 (en) Influenza A virus variants
US11911394B2 (en) Compound and method for the prevention of transmission of influenza virus
Hussein et al. Identification of entry inhibitors with 4-aminopiperidine scaffold targeting group 1 influenza A virus
US8894997B2 (en) Monoclonal antibodies to influenza H1N1 virus uses thereof
WO2011126071A1 (fr) Agent capable d'inhiber une infection virale et/ou de traiter une maladie infectieuse et méthode d'inhibition d'une infection virale et/ou de traitement d'une maladie infectieuse
US20100266606A1 (en) Antibody therapy for highly pathogenic avian influenza virus
Li et al. Hemagglutinin stability determines influenza A virus susceptibility to a broad-spectrum fusion inhibitor Arbidol
WO2012142492A2 (fr) Procédés permettant d'inhiber la réplication de virus
CN114224896A (zh) 病毒感染症的预防和早期治疗用组合物
US11337988B2 (en) Use of ouabain antagonists to inhibit viral infection
WO2017162704A1 (fr) Inhibiteurs de fpr2, compositions et utilisations de ceux-ci pour moduler la réplication du virus de la grippe
Si et al. Entry properties and entry inhibitors of a human H7N9 influenza virus
Henke et al. The envelope proteins from SARS-CoV-2 and SARS-CoV potently reduce the infectivity of human immunodeficiency virus type 1 (HIV-1)
US9783482B2 (en) Antiviral compositions directed against the influenza virus nucleoprotein
Jeon et al. Inhibition of KIF20A suppresses the replication of influenza A virus by inhibiting viral entry
서수경 The role of ARF1 in unconventional secretion of transmembrane protein
La Rosa et al. Inactivation of the Niemann Pick C1 cholesterol transporter 1 (NPC1) restricts SARS-CoV-2 infection
Radic A Novel Role for SCAMP3 as an Innate Immune Factor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11765971

Country of ref document: EP

Kind code of ref document: A1

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11765971

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP